Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vasco animal health products c/- virbac - not entered yet - parasiticides - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - not applicable (vet)

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

United States - English - NLM (National Library of Medicine)

tolmar inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - leuprolide acetate 7.5 mg in 0.25 ml - eligard® is indicated for the palliative treatment of advanced prostate cancer. hypersensitivity eligard® is contraindicated in patients with hypersensitivity to gnrh, gnrh agonist analogs or any of the components of eligard® .  anaphylactic reactions to synthetic gnrh or gnrh agonist analogs have been reported in the literature. risk summary based on findings in animal studies and mechanism of action, eligard® may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. expected hormonal changes that occur with eligard® treatment increase the risk for pregnancy loss. in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation in rats. advise pregnant patients and females of reproductive potential of the potential risk to the fetus (see data) . animal data in animal developmental and reproduc

United States - English - NLM (National Library of Medicine)

tolmar inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - eligard®  is indicated for the treatment of advanced prostate cancer. hypersensitivity eligard is contraindicated in patients with hypersensitivity to gnrh, gnrh agonist analogs or any of the components of eligard.  anaphylactic reactions to synthetic gnrh or gnrh agonist analogs have been reported in the literature. risk summary based on findings in animal studies and mechanism of action, eligard may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. expected hormonal changes that occur with eligard treatment increase the risk for pregnancy loss. in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation in rats. advise pregnant patients and females of reproductive potential of the potential risk to the fetus (see data) . animal data in animal developmental and reproductive studies, majo

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.